Compare Mesoblast Limited (MESO) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Raymond James Financial, Inc. — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while Raymond James Financial, Inc. trades at $180.14 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 15.7× Mesoblast Limited's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | RJF | |
|---|---|---|
Market Cap | $2.21B | $34.63B |
Sector | Technology | Financials |
52-Week High | $20.96 | $180.55 |
52-Week Low | $12.88 | $140.89 |
Enterprise Value | $2.21B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Raymond James Financial (RJF) trades at $179.09, up 1.43% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows consistent revenue growth, reaching $13.84B in 2025, and a solid net income margin of 15.37%. Recent news highlights record Q3 2026 revenues and strategic acquisitions as key growth drivers.
The outlook is positive with a consensus price target of $183.75, though risks include market volatility and execution of growth initiatives. The stock presents an opportunity based on fundamental strength and analyst support, balanced by the need to monitor expense management and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
